As part of its second quarter earnings call, MorphoSys has announced the discontinued development of its CD38 antibody MOR202 in myeloma and lung cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,